Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

The Role of Canonical Polycomb Repressive Complex 1 in Histone H3 K27M Gliomas

FY 2022-23

Summary
Pediatric high-grade gliomas (pHGGs) are aggressive brain tumours with dismal prognoses. Genetic mutations on histone H3 changing lysine 27 to methionine (H3K27M) define a unique subgroup of pHGGs. This mutation impairs the ability of Polycomb Repressive Complex 2 (PRC2) to trimethylate H3K27 (H3K27me3). This chemical modification is normally required to establish heterochromatin-based gene silencing and control cell identity. H3K27me3 is recognized by the canonical PRC1 (cPRC1) complex via a chromodomain located on one of several chromobox (CBX) proteins, contributing to chromatin compaction and gene silencing. H3K27M mutations impair glial cell differentiation, which is thought to account for pHGG tumour development. This project aims to determine the function of cPRC1 in H3K27M gliomas. To do so, we will apply molecular techniques to study the role of cPRC1 in H3K27M glioma cell lines, including immunofluorescence imaging of CBX proteins, chromatin immunocleavage-based genomic profiling of cPRC1 subunits, and Hi-C chromatin architecture mapping. We will then reduce cPRC1 function in these cells using short-hairpin RNA (shRNA) knockdown of CBX proteins as well as small molecule chemical probes that obstruct CBX chromodomain interactions with H3K27me3. Using these altered cells, we will investigate the differentiation potential compared to unaltered H3K27M cells using various in vivo and in vitro techniques. These results will potentially contribute understanding to the mechanism by which H3K27M mutations cause these tumours, and may aid to the identification of new therapeutic targets.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486084
Name
Ptack Adam
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Role of Canonical Polycomb Repressive Complex 1 in Histone H3 K27M Gliomas
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Brain Tumors; Cancer; Dipg; Epigenetics; Histone Modifications; Polycomb Repressive Complex
Abstract
Pediatric high-grade gliomas (pHGGs) are aggressive brain tumours with dismal prognoses. Genetic mutations on histone H3 changing lysine 27 to methionine (H3K27M) define a unique subgroup of pHGGs. This mutation impairs the ability of Polycomb Repressive Complex 2 (PRC2) to trimethylate H3K27 (H3K27me3). This chemical modification is normally required to establish heterochromatin-based gene silencing and control cell identity. H3K27me3 is recognized by the canonical PRC1 (cPRC1) complex via a chromodomain located on one of several chromobox (CBX) proteins, contributing to chromatin compaction and gene silencing. H3K27M mutations impair glial cell differentiation, which is thought to account for pHGG tumour development. This project aims to determine the function of cPRC1 in H3K27M gliomas. To do so, we will apply molecular techniques to study the role of cPRC1 in H3K27M glioma cell lines, including immunofluorescence imaging of CBX proteins, chromatin immunocleavage-based genomic profiling of cPRC1 subunits, and Hi-C chromatin architecture mapping. We will then reduce cPRC1 function in these cells using short-hairpin RNA (shRNA) knockdown of CBX proteins as well as small molecule chemical probes that obstruct CBX chromodomain interactions with H3K27me3. Using these altered cells, we will investigate the differentiation potential compared to unaltered H3K27M cells using various in vivo and in vitro techniques. These results will potentially contribute understanding to the mechanism by which H3K27M mutations cause these tumours, and may aid to the identification of new therapeutic targets.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ptack, Adam
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~